Science AI Journal
Medicine · Research topic

Open research questions in Renal cell carcinoma treatment

39 unresolved questions extracted from the limitations and future-work sections of 413 Renal cell carcinoma treatment papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • While MWA is widely used in human medicine for small renal tumors and has been reported in other tumor types in dogs, it has not been described in cats.

    EXPRESS: Microwave ablation of a primary renal tumor in a cat · 2026 · DOI

  • in childhood. Clin Cancer Res 2017;23:e76-82. 8. Lattouf JB, Pautler SE, Reaume MN, et al. Structured assessment and follow-up for patients with hereditary kidney tumour syndromes. Can Urol Assoc J 2016;10:E214- 22. 4 # Cheung et al #Hong Kong Medical Journal ©2026 Hong Kong Academy of Medicine.

    Hereditary leiomyomatosis and renal cell carcinoma: a case series · 2026 · DOI

  • However, it remains unclear whether the detrimental effect of pT4 stage is driven by unfavorable tumor characteristics such as larger tumor size, higher tumor grade, and less favor- able histological subtypes, or whether it is independently attributable to adjacent organ invasion. Studies that specifically addressed this patient sub- group have not been reported. Consequently, the incremental prognostic impact of pT4 within the M0 setting has remained insufficiently defined.

    Prognostic impact of adjacent organ invasion on cancer-specific mortality in non-metastatic renal cell carcinoma · 2026 · DOI

  • ABSTRACT Intratumor bacteria (ITB) have emerged as key modulators in various malignancies; however, their role in clear-cell renal cell carcinoma (ccRCC) remains unclear and elusive.

    A comprehensive study of intratumor bacteria in clear-cell renal cell carcinoma identifies <i>Cutibacterium acnes</i> as a protector via suppression of macrophage M2 polarization · 2026 · DOI

  • While PD-1 and PD-L1 have been extensively studied, the prevalence and distribution of other immune checkpoints (ICs) and their relationship with epithelial-to-mesenchymal transition (EMT) remain poorly characterised.

    Interplay Between Immune Checkpoint Modulators and the Epithelial-to-Mesenchymal Transition Axis in Clear Cell Renal Cell Carcinoma · 2026 · DOI

  • Conclusions: Collectively, this study identifies an EMT–IC axis in ccRCC and demonstrates its relevance to tumour biology and patient outcomes, highlighting LAG3 and NT5E as potential prognostic markers and therapeutic targets that warrant further investigation.

    Interplay Between Immune Checkpoint Modulators and the Epithelial-to-Mesenchymal Transition Axis in Clear Cell Renal Cell Carcinoma · 2026 · DOI

  • A major limitation of this study is the unspecified timing of the transfusions. Further research and continuous evaluation of transfusion practices are warranted to validate these findings and develop tailored transfusion protocols for patients undergoing PN to enhance overall quality of care.

    Risk Factors and Complications of Transfusion Following Partial Nephrectomy · 2026 · DOI

  • It is assumed that future developments in the treatment of renal cell carcinoma (RCC) will focus more and more on the development of risk-adaptive and more individualized treatment regimes that will optimize both the oncologic outcomes and ensure renal survival over the long term.

    Diagnostic and Therapeutic Innovations in Renal Cell Carcinoma: A Urologic Oncology Review · 2026 · DOI

  • However, the role of cytoreductive nephrectomy (CN) in the IO-TKI era, particularly for rare and understudied histologies such as non-clear-cell RCC, remains poorly understood.

    The Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Carcinoma in the Era of Emerging Systemic Therapy: A Retrospective Cohort Study · 2026 · DOI

  • RNA-based T-effector signatures capture cytotoxic immune biology and have been associated with ICI response in clinical trial cohorts; however, their clinical implementation is limited by the marked spatial heterogeneity of ccRCC, as well as cost, long turnaround time, sample quality requirements, and limited accessibility.

    A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets · 2026 · DOI

  • Future work will focus on (i) external multi-institutional validation to quantify domain shift; (ii) integration of volumetric exploration of 3D context differentiable calibration objectives; and (iv) extension to Bosniak risk stratification and urinary stone composition prediction. Fourth, the current evaluation is restricted to axial and coronal CT planes and does not account for volumetric or multi-phase information, which could improve discrimination in challenging cases such as fat-poor angiomyolipomas or early-stage transitional cell carcinomas.

    NephroNet: a calibration-aware, patient-disjoint benchmark for multiclass kidney CT classification with a compact depthwise-separable CNN · 2026 · DOI

  • Moreover, while indirect trial evidence indicates potential heterogeneity in effectiveness across individual ICI–TKI regimens [19], the available real-world data were limited and insufficient for robust comparative assess- ment.

    Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review · 2026 · DOI

  • Oligometastatic RCC, frequently defined as the presence of fewer than five metastatic lesions, is increasingly recognised as a clinically and prognostically distinct disease state, yet standardised treatment algorithms remain lacking.

    Oligometastatic RCC: Challenges and Emerging Therapeutic Strategies · 2026 · DOI

  • Summary Computerized methods, including AI, are showing increased application in kidney pathology for a wide variety of clinical and histopathologic parameter assessment, including interstitial fibrosis; however, further studies are needed to characterize the performance of AI and handcrafted methods; and additional work is needed to fully integrate computerized methods into routine pathology practice.

    Assessing interstitial fibrosis and tubular atrophy in kidney biopsies artificial intelligence versus humans · 2026 · DOI

  • Although hemorrhagic events are recognized adverse effects of these agents, intracranial hemorrhage is rare, and the safety of re-administration of VEGFR TKIs after central nervous system (CNS) hemorrhage remains unclear.

    Recurrent intracranial hemorrhage without brain metastasis after VEGFR TKI rechallenge in metastatic renal cell carcinoma: a case report and literature review · 2026 · DOI

  • It remains unknown whether differences in overall and cause-specific survival endpoints exist between African American and European American localized pRCC patients treated with nephrectomy. As a result, the specific sur- vival outcomes applicable to pRCC remain unknown. Moreover, prior studies were limited by the lack of specific focus on localized stage and by heterogeneous treatment strate- gies extending beyond nephrectomy, including untreated patients [6, 7].

    Survival Differences of Localized Papillary Renal Cell Carcinoma in African Americans vs. European Americans · 2026 · DOI

  • Considering the above considerations, we propose the fol- lowing areas for future research: • Standardizing definitions: Establish a unified operational definition of overdiagnosis in RCC, distinguishing it from overtreatment and overdetection. • AI-driven risk stratification: Validate AI and radiomic models across multi-institutional cohorts to enhance reli- ability and fairness. • Molecular validation studies: Expand multi-omic integra- tion to identify robust molecular indicators of indolence. • Prospective longitudinal cohorts: Develop large surveil- lance registries to track natural history and refine inter- vention thresholds. • Language reframing: Consider terminology changes— such as “clinically indolent RCC”—to support commu- nication and reduce overtreatment bias.

    Overdiagnosis in renal cancer: the hidden consequence of modern imaging · 2026 · DOI

  • This study is subject to several important limitations that should be considered when interpreting the findings. The overall strength of evidence is limited by the predominance of observational studies and relatively small sample sizes across included reports. Substantial heterogeneity was observed for key outcomes, likely reflecting differences in surgeon experience, tumor complexity, surgical approach, and institutional practices, which reduces the reliability of pooled estimates. In addition, many studies represent early experiences with emerging robotic platforms, introducing potential learning-curve and early adoption bias, as these technologies are often implemented in high-volume centers by experienced surgeons. Follow-up duration was generally short, and important long-term outcomes, including oncologic control and renal functional preservation, were inconsistently reported. Sev- eral clinically relevant endpoints, such as complications and oncologic outcomes, could not be quantitatively syn- thesized due to heterogeneous definitions and reporting practices, and were therefore assessed descriptively. Fur- thermore, the lack of standardized reporting across studies limited the ability to perform subgroup or meta-regression analyses, particularly for factors such as tumor complexity and surgeon expertise. Tumor complexity represents a major determinant of perioperative outcomes in RAPN. Although R.E.N.A.L. nephrometry scores were reported in several included stud- ies, reporting was heterogeneous and incomplete, preventing 1 3Journal of Robotic Surgery (2026) 20:518 518 Page 14 of 15 formal stratified analyses or meta-regression based on tumor complexity. Consequently, differences observed between robotic platforms may partly reflect variation in case mix rather than intrinsic platform-related performance. Finally, cost-effectiveness data were largely unavailable, despite their critical importance in evaluating the broader adoption and sustainability of emerging robotic platforms in clinical practice. Furthermore, the absence of cost-effec- tiveness data highlights an important gap in the available literature. Also, industry-sponsored studies on comparisons between robotic systems may introduce potential biases, as they often favor the sponsor’s platform, limiting the gen- eralizability of our findings. Despite these limitations, our study provides valuable insights into the current and emerg- ing robotic platforms for RAPN and lays the groundwork for future research and clinical practice.

    Emerging robotic platforms in partial nephrectomy: a comparative systematic review and network meta-analysis · 2026 · DOI

  • Future research priorities include refining the expression profiling of TSA/TAA in tumor versus healthy tissues, the evaluation of different tumor antigen-specific treatment strategies in vitro, ex vivo, in vivo in animal models and in pilot clinical trials followed by the investigation of combination strategies with other therapeutic modalities.

    Discovery of tumor antigens in renal cell carcinoma and prospects for clinical application · 2026 · DOI

  • Insufficient comparative data on optimal management strategies between multimodal approaches (TURBT plus systemic therapy) versus TURBT alone for metastatic RCC to bladder.

    Metastatic Clear Cell Renal Cell Carcinoma Masquerading as Urinary Bladder Tumor: A Report of a Rare Case · 2026 · DOI

  • Lack of established clinical guidelines or protocols for screening and early detection of bladder metastasis in patients with apparently localized RCC post-nephrectomy.

    Metastatic Clear Cell Renal Cell Carcinoma Masquerading as Urinary Bladder Tumor: A Report of a Rare Case · 2026 · DOI

  • CONCLUSIONS: Given the study's findings and available research, caution is warranted when drawing conclusions about the potential inhibitory effect of ELF-EMF on ccRCC progression.

    Extremely low-frequency electromagnetic field (ELF-EMF) induced alterations in gene expression and cytokine secretion in clear cell renal carcinoma cells · 2024 · DOI

  • There is no consensus on the optimal management of advanced RCC and complication is due — at least in part — to different outcomes of patients belonging to particular prognostic categories.

    Current options in the management of advanced renal-cell carcinoma — an update · 2010

  • Limited understanding of mechanisms underlying the predilection for bladder metastasis in apparently localized RCC cases.

    Metastatic Clear Cell Renal Cell Carcinoma Masquerading as Urinary Bladder Tumor: A Report of a Rare Case · 2026 · DOI

  • Because PROs were measured every 6 weeks, which corresponded to “off-treatment” weeks in the sunitinib arm, results may not be representative of average symptom burden with sunitinib.

    Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial · 2024 · DOI

Most-cited papers in Renal cell carcinoma treatment

Most recent work

Find a gap in your own Renal cell carcinoma treatment sub-topic

This page shows what the Renal cell carcinoma treatment literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
39 open questions have been extracted from the limitations and future-work passages of 413 Renal cell carcinoma treatment papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.